Scandinavian Real Heart AB (SE:HEART)
:HEART
Want to see SE:HEART full AI Analyst Report?
HEART Stock Chart & Stats
kr25.80
kr0.30(2.04%)
At close: 4:00 PM EST
kr25.80
kr0.30(2.04%)
Day’s Range― - ―
52-Week Rangekr12.06 - kr29.89
Previous CloseN/A
Volume1.18K
Average Volume (3M)7.92K
Market Cap
kr177.95M
Enterprise Valuekr75.80M
Total Cash (Recent Filing)kr27.94M
Total Debt (Recent Filing)kr5.40M
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,997,408
10 Day Avg. Volume3,221
30 Day Avg. Volume7,918
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr42.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage reduces fixed financing obligations and lowers bankruptcy risk, providing financial flexibility to support clinical programs or licensing discussions. Over the next 2–6 months this stability in capital structure helps preserve strategic options while the company pursues funding or partnerships.
Focused, High-barrier ProductA clear strategic focus on an implantable total artificial heart targets a large unmet need and benefits from high technical barriers, regulatory inertia, and potential IP protection. This structural positioning creates a durable competitive opportunity if clinical and regulatory progress continues.
Lean Operating FootprintA very small headcount implies lower fixed administrative costs and potential capital efficiency, which can extend runway between financings. For an R&D-intensive medtech firm, a lean core team can preserve cash while outsourcing costly development phases.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the company cannot self-fund development and must rely on external financing or partners. Over 2–6 months this elevates execution risk, increases dilution or covenant exposure, and constrains strategic flexibility.
Effectively Pre-revenueWith minimal or no recurring revenue and continued operating losses, the firm lacks validated commercial unit economics. This structural stage implies a multi-period path to sustainable revenues, keeping financing needs and execution risk elevated for the foreseeable future.
Eroding Equity BaseA material decline in equity and assets over several years reflects accumulated losses and/or dilution, signaling weakening balance-sheet resilience. Persisting this trend raises the probability of further equity issuance or asset sales, which can dilute shareholders and limit long-term strategic leeway.
HEART FAQ
What was Scandinavian Real Heart AB’s price range in the past 12 months?
Scandinavian Real Heart AB lowest stock price was kr12.06 and its highest was kr29.89 in the past 12 months.
What is Scandinavian Real Heart AB’s market cap?
Scandinavian Real Heart AB’s market cap is kr177.95M.
When is Scandinavian Real Heart AB’s upcoming earnings report date?
Scandinavian Real Heart AB’s upcoming earnings report date is May 14, 2026 which is in 10 days.
How were Scandinavian Real Heart AB’s earnings last quarter?
Currently, no data Available
Is Scandinavian Real Heart AB overvalued?
According to Wall Street analysts Scandinavian Real Heart AB’s price is currently Overvalued.
Does Scandinavian Real Heart AB pay dividends?
Scandinavian Real Heart AB does not currently pay dividends.
What is Scandinavian Real Heart AB’s EPS estimate?
Scandinavian Real Heart AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandinavian Real Heart AB have?
Scandinavian Real Heart AB has 9,997,408 shares outstanding.
What happened to Scandinavian Real Heart AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scandinavian Real Heart AB?
Currently, no hedge funds are holding shares in SE:HEART
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scandinavian Real Heart AB
Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. It engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, PulsePump, and Sternal Prosthesis products. The company was incorporated in 2007 and is based in Västerås, Sweden.